Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Patients undergoing hemodialysis (HD) live with a high symptom burden that is not adequately reflected by conventional clinical metrics. Such indicators fail to capture subjective wellbeing and the daily impact of symptoms. Patient-reported outcome measures (PROMs) offer a structured way to systematically include patients’ perspectives, enabling individualized, patient-centered care and supporting quality improvement in dialysis services.
The IPOS-Renal questionnaire was administered once per year in a national, multicenter cohort of adult patients receiving in-center HD or hemodiafiltration (HDF) during 2023 and 2024. Participation was voluntary and anonymized. Responses were analyzed to characterize symptom prevalence and explore year-to-year consistency.
In 2024, 1,093 patients completed the questionnaire (82% response rate), with 59.5% male. In 2023, 761 patients responded (56% response rate), with 59% male. Most respondents were aged 66–85 years (57.3% in 2024; 53.8% in 2023). The dialysis-vintage distribution showed 33.0% with 1–3 years on HD in 2024 versus 44.2% in 2023. The five most frequent symptoms were highly consistent between years. In 2024, the leading symptoms were difficulty sleeping (30%), pain (27%), reduced mobility (24%), weakness/lack of energy (24%), and lack of appetite (18%). In 2023, corresponding rates were 30%, 26%, 25%, 26%, and 19%, respectively. Only one of the top five symptoms differed between years, indicating a stable pattern of symptom burden across the cohort.
Symptoms such as sleep disturbances and pain remain highly prevalent and impactful among HD/HDF patients yet are not routinely identified or treated within standard care pathways. The regular use of PROMs like IPOS-Renal complements traditional clinical indicators, allowing care teams to capture what matters most to patients, improve communication, and individualize treatment strategies. Sustained integration of PROMs in routine dialysis practice may support more person-centered and value-based kidney care.
